News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
The phase III NETTER-2 trial published in The Lancet and presented by Pamela Kunz at ASCO24 – Yale Cancer Center
Jun 10, 2024, 07:25

The phase III NETTER-2 trial published in The Lancet and presented by Pamela Kunz at ASCO24 – Yale Cancer Center

Yale Cancer Center shared a post on X:

“The phase III NETTER-2 trial published in The Lancet and presented by Pamela Kunz at ASCO24 showed Lu-Dotatate should be considered a new standard of care in 1st line therapy for pts with grade 2 or 3 advanced gastroenteropancreatic neuroendocrinetumors.”

Additional information.
Source: Yale Cancer Center/X

ASCO24 cancer cancer treatment clinical trial results first-line therapy GEP-NETS Lu-Dotatate neuroendocrine tumors new standard of care OncoDaily Oncology oncology research Pamela Kunz phase III NETTER-2 trial The Lancet Yale Cancer Center
Special Coverage
Blog
Jan 9, 2025, 17:18
Fumiko Ladd Chino: 2025  ASCO JCO Journals Editorial Fellow Application is OPEN
Insight
Jan 9, 2025, 17:18
Jessica MacIntyre: Excited for this year’s 50th Annual Oncology Nursing Society Congress
Blog
Jan 9, 2025, 17:04
Mehdi Hamadani: Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide
Blog
Jan 9, 2025, 16:48
Design of a Fc-engineered tetravalent bispecific antibody targeting PD-1 and VEGF with cooperative biological effects
Blog
Jan 9, 2025, 16:41
Elisabetta Munzone: Harmonizing EHRs in Italy for Better Healthcare Outcomes and Cost Reduction
Blog
Jan 9, 2025, 16:38
Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis
Blog
Jan 9, 2025, 16:35
Ahmed Kotb: Ph-like ALL Signaling Pathways and Targets
Blog
Jan 9, 2025, 16:32
Priorities of ESTRO for engagement within the EURAMED framework
Blog
Jan 9, 2025, 16:29
Aakash Desai: Rybrevant + Lazcluze to show clinically meaningful improvement in OS vs osimertinib
Blog
Jan 9, 2025, 16:22
Isabel Preeshagul: Survey on addressing barriers to clinical trial accrual in patients with lung cancer
Blog
Jan 9, 2025, 16:20
Saddened to learn of the unexpected passing of Prof. Petra Feyer - MASCC
Blog
Jan 9, 2025, 16:07
Eric Racine: The Patient Advocacy Voices Podcast is Back for 2025